HISPANA | Directorio nacional de recursos digitales > Datos de registro

Está en:  › Datos de registro

Linked Open Data

7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility

Identificadores del recurso

Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).

https://hdl.handle.net/20.500.13003/20140

10.3390/biom13121769

2218-273X

38136640

L2027318853

2-s2.0-85180427298

001130755700001

Procedencia

(Docusalut. Repositorio institucional del sistema sanitario público de las Islas Baleares)

Ficha

Título:: 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility
Tema:: Uric Acid; Solubility; Theobromine; Caffeine; Cafeína; Solubilidad; Ácido Úrico; Teobromina
Descripción:: Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.; This research was funded by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, MCIN/AEI/10.13039/501100011033, with grant number PID2019-104331RB-I00.
Idioma:: English
Relación:: MCIN/AEI/10.13039/501100011033; PID2019-104331RB-I00; https://doi.org/10.3390/biom13121769
Autor/Productor:: Costa-Bauza, Antonia; Grases, Felix
Derechos:: Atribución 4.0 Internacional; http://creativecommons.org/licenses/by/4.0/; open access
Fecha:: 2024-01-29T12:01:01Z; 2023-12-10
Tipo de recurso:: research article

oai_dc

<?xml version="1.0" encoding="UTF-8" ?>

<oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
1. <dc:title>7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</dc:title>
2. <dc:creator>Costa-Bauza, Antonia</dc:creator>
3. <dc:creator>Grases, Felix</dc:creator>
4. <dc:subject>Uric Acid</dc:subject>
5. <dc:subject>Solubility</dc:subject>
6. <dc:subject>Theobromine</dc:subject>
7. <dc:subject>Caffeine</dc:subject>
8. <dc:subject>Cafeína</dc:subject>
9. <dc:subject>Solubilidad</dc:subject>
10. <dc:subject>Ácido Úrico</dc:subject>
11. <dc:subject>Teobromina</dc:subject>
12. <dc:description>Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</dc:description>
13. <dc:description>This research was funded by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, MCIN/AEI/10.13039/501100011033, with grant number PID2019-104331RB-I00.</dc:description>
14. <dc:date>2024-01-29T12:01:01Z</dc:date>
15. <dc:date>2024-01-29T12:01:01Z</dc:date>
16. <dc:date>2023-12-10</dc:date>
17. <dc:type>research article</dc:type>
18. <dc:identifier>Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</dc:identifier>
19. <dc:identifier>https://hdl.handle.net/20.500.13003/20140</dc:identifier>
20. <dc:identifier>10.3390/biom13121769</dc:identifier>
21. <dc:identifier>2218-273X</dc:identifier>
22. <dc:identifier>38136640</dc:identifier>
23. <dc:identifier>L2027318853</dc:identifier>
24. <dc:identifier>2-s2.0-85180427298</dc:identifier>
25. <dc:identifier>001130755700001</dc:identifier>
26. <dc:language>eng</dc:language>
27. <dc:relation>MCIN/AEI/10.13039/501100011033</dc:relation>
28. <dc:relation>PID2019-104331RB-I00</dc:relation>
29. <dc:relation>https://doi.org/10.3390/biom13121769</dc:relation>
30. <dc:rights>Atribución 4.0 Internacional</dc:rights>
31. <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
32. <dc:rights>open access</dc:rights>
</oai_dc:dc>

didl

<?xml version="1.0" encoding="UTF-8" ?>

<d:DIDL schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">
1. <d:DIDLInfo>
  1. <dcterms:created schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2024-01-29T12:01:01Z</dcterms:created>
  </d:DIDLInfo>
2. <d:Item id="hdl_20.500.13003_20140">
  1. <d:Descriptor>
    1. <d:Statement mimeType="application/xml; charset=utf-8">
      1. <dii:Identifier schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:20.500.13003/20140</dii:Identifier>
      </d:Statement>
    </d:Descriptor>
  2. <d:Descriptor>
    1. <d:Statement mimeType="application/xml; charset=utf-8">
      1. <oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
        <dc:title>7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</dc:title>
        <dc:creator>Costa-Bauza, Antonia</dc:creator>
        <dc:creator>Grases, Felix</dc:creator>
        <dc:description>Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</dc:description>
        <dc:date>2024-01-29T12:01:01Z</dc:date>
        <dc:date>2024-01-29T12:01:01Z</dc:date>
        <dc:date>2023-12-10</dc:date>
        <dc:type>research article</dc:type>
        <dc:identifier>Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</dc:identifier>
        <dc:identifier>https://hdl.handle.net/20.500.13003/20140</dc:identifier>
        <dc:identifier>10.3390/biom13121769</dc:identifier>
        <dc:identifier>2218-273X</dc:identifier>
        <dc:identifier>38136640</dc:identifier>
        <dc:identifier>L2027318853</dc:identifier>
        <dc:identifier>2-s2.0-85180427298</dc:identifier>
        <dc:identifier>001130755700001</dc:identifier>
        <dc:language>eng</dc:language>
        <dc:relation>MCIN/AEI/10.13039/501100011033</dc:relation>
        <dc:relation>PID2019-104331RB-I00</dc:relation>
        <dc:relation>https://doi.org/10.3390/biom13121769</dc:relation>
        <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
        <dc:rights>open access</dc:rights>
        <dc:rights>Atribución 4.0 Internacional</dc:rights>
        </oai_dc:dc>
      </d:Statement>
    </d:Descriptor>
  3. <d:Component id="20.500.13003_20140_1">
    1. <d:Resource mimeType="application/pdf" ref="https://docusalut.com/bitstream/20.500.13003/20140/1/Biomolecules_2023-13-12-1769.pdf" />
    </d:Component>
  </d:Item>
</d:DIDL>

dim

<?xml version="1.0" encoding="UTF-8" ?>

<dim:dim schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
1. <dim:field authority="170" confidence="500" element="contributor" mdschema="dc" orcid_id="0000-0003-0647-4154" qualifier="author">Costa-Bauza, Antonia</dim:field>
2. <dim:field authority="340" confidence="500" element="contributor" mdschema="dc" orcid_id="" qualifier="author">Grases, Felix</dim:field>
3. <dim:field element="date" mdschema="dc" qualifier="accessioned">2024-01-29T12:01:01Z</dim:field>
4. <dim:field element="date" mdschema="dc" qualifier="available">2024-01-29T12:01:01Z</dim:field>
5. <dim:field element="date" mdschema="dc" qualifier="issued">2023-12-10</dim:field>
6. <dim:field element="identifier" lang="en" mdschema="dc" qualifier="citation">Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</dim:field>
7. <dim:field element="identifier" mdschema="dc" qualifier="uri">https://hdl.handle.net/20.500.13003/20140</dim:field>
8. <dim:field element="identifier" mdschema="dc" qualifier="doi">10.3390/biom13121769</dim:field>
9. <dim:field element="identifier" mdschema="dc" qualifier="essn">2218-273X</dim:field>
10. <dim:field element="identifier" mdschema="dc" qualifier="pmid">38136640</dim:field>
11. <dim:field element="identifier" mdschema="dc" qualifier="pui">L2027318853</dim:field>
12. <dim:field element="identifier" mdschema="dc" qualifier="scopus">2-s2.0-85180427298</dim:field>
13. <dim:field element="identifier" mdschema="dc" qualifier="wos">001130755700001</dim:field>
14. <dim:field element="description" lang="en" mdschema="dc" qualifier="abstract">Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</dim:field>
15. <dim:field element="description" lang="en" mdschema="dc" qualifier="fundingtext">This research was funded by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, MCIN/AEI/10.13039/501100011033, with grant number PID2019-104331RB-I00.</dim:field>
16. <dim:field element="language" lang="en" mdschema="dc" qualifier="iso">eng</dim:field>
17. <dim:field element="rights" lang="*" mdschema="dc">Atribución 4.0 Internacional</dim:field>
18. <dim:field element="rights" lang="*" mdschema="dc" qualifier="uri">http://creativecommons.org/licenses/by/4.0/</dim:field>
19. <dim:field element="rights" lang="en" mdschema="dc" qualifier="accessRights">open access</dim:field>
20. <dim:field authority="D014527" confidence="500" element="subject" lang="*" mdschema="dc" qualifier="mesh">Uric Acid</dim:field>
21. <dim:field authority="D012995" confidence="500" element="subject" lang="*" mdschema="dc" qualifier="mesh">Solubility</dim:field>
22. <dim:field authority="D013805" confidence="500" element="subject" lang="*" mdschema="dc" qualifier="mesh">Theobromine</dim:field>
23. <dim:field authority="D002110" confidence="500" element="subject" lang="*" mdschema="dc" qualifier="mesh">Caffeine</dim:field>
24. <dim:field authority="DECSD002110" confidence="500" element="subject" lang="*" mdschema="dc" qualifier="decs">Cafeína</dim:field>
25. <dim:field authority="DECSD012995" confidence="500" element="subject" lang="*" mdschema="dc" qualifier="decs">Solubilidad</dim:field>
26. <dim:field authority="DECSD014527" confidence="500" element="subject" lang="*" mdschema="dc" qualifier="decs">Ácido Úrico</dim:field>
27. <dim:field authority="DECSD013805" confidence="500" element="subject" lang="*" mdschema="dc" qualifier="decs">Teobromina</dim:field>
28. <dim:field element="title" lang="en" mdschema="dc">7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</dim:field>
29. <dim:field element="type" lang="en" mdschema="dc">research article</dim:field>
30. <dim:field element="issue" lang="en" mdschema="dc" qualifier="number">12</dim:field>
31. <dim:field element="journal" lang="en" mdschema="dc" qualifier="title">Biomolecules</dim:field>
32. <dim:field element="relation" lang="en" mdschema="dc" qualifier="projectID">MCIN/AEI/10.13039/501100011033</dim:field>
33. <dim:field element="relation" lang="en" mdschema="dc" qualifier="projectID">PID2019-104331RB-I00</dim:field>
34. <dim:field element="relation" lang="en" mdschema="dc" qualifier="publisherversion">https://doi.org/10.3390/biom13121769</dim:field>
35. <dim:field element="volume" lang="en" mdschema="dc" qualifier="number">13</dim:field>
</dim:dim>

etdms

<?xml version="1.0" encoding="UTF-8" ?>

<thesis schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">
1. <title>7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</title>
2. <creator>Costa-Bauza, Antonia</creator>
3. <creator>Grases, Felix</creator>
4. <description>Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</description>
5. <date>2024-01-29</date>
6. <date>2024-01-29</date>
7. <date>2023-12-10</date>
8. <type>research article</type>
9. <identifier>Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</identifier>
10. <identifier>https://hdl.handle.net/20.500.13003/20140</identifier>
11. <identifier>10.3390/biom13121769</identifier>
12. <identifier>2218-273X</identifier>
13. <identifier>38136640</identifier>
14. <identifier>L2027318853</identifier>
15. <identifier>2-s2.0-85180427298</identifier>
16. <identifier>001130755700001</identifier>
17. <language>eng</language>
18. <relation>MCIN/AEI/10.13039/501100011033</relation>
19. <relation>PID2019-104331RB-I00</relation>
20. <relation>https://doi.org/10.3390/biom13121769</relation>
21. <rights>http://creativecommons.org/licenses/by/4.0/</rights>
22. <rights>open access</rights>
23. <rights>Atribución 4.0 Internacional</rights>
</thesis>

marc

<?xml version="1.0" encoding="UTF-8" ?>

<record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">
1. <leader>00925njm 22002777a 4500</leader>
2. <datafield ind1=" " ind2=" " tag="042">
  1. <subfield code="a">dc</subfield>
  </datafield>
3. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Costa-Bauza, Antonia</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
4. <datafield ind1=" " ind2=" " tag="720">
  1. <subfield code="a">Grases, Felix</subfield>
  2. <subfield code="e">author</subfield>
  </datafield>
5. <datafield ind1=" " ind2=" " tag="260">
  1. <subfield code="c">2023-12-10</subfield>
  </datafield>
6. <datafield ind1=" " ind2=" " tag="520">
  1. <subfield code="a">Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</subfield>
  </datafield>
7. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</subfield>
  </datafield>
8. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">https://hdl.handle.net/20.500.13003/20140</subfield>
  </datafield>
9. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">10.3390/biom13121769</subfield>
  </datafield>
10. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">2218-273X</subfield>
  </datafield>
11. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">38136640</subfield>
  </datafield>
12. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">L2027318853</subfield>
  </datafield>
13. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">2-s2.0-85180427298</subfield>
  </datafield>
14. <datafield ind1="8" ind2=" " tag="024">
  1. <subfield code="a">001130755700001</subfield>
  </datafield>
15. <datafield ind1="0" ind2="0" tag="245">
  1. <subfield code="a">7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</subfield>
  </datafield>
</record>

mets

<?xml version="1.0" encoding="UTF-8" ?>

<mets ID=" DSpace_ITEM_20.500.13003-20140" OBJID=" hdl:20.500.13003/20140" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd">
1. <metsHdr CREATEDATE="2024-09-29T03:57:33Z">
  1. <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">
    1. <name>Docusalut</name>
    </agent>
  </metsHdr>
2. <dmdSec ID="DMD_20.500.13003_20140">
  1. <mdWrap MDTYPE="MODS">
    1. <xmlData schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
      1. <mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Costa-Bauza, Antonia</mods:namePart>
        </mods:name>
        <mods:name>
        <mods:role>
        <mods:roleTerm type="text">author</mods:roleTerm>
        </mods:role>
        <mods:namePart>Grases, Felix</mods:namePart>
        </mods:name>
        <mods:extension>
        <mods:dateAccessioned encoding="iso8601">2024-01-29T12:01:01Z</mods:dateAccessioned>
        </mods:extension>
        <mods:extension>
        <mods:dateAvailable encoding="iso8601">2024-01-29T12:01:01Z</mods:dateAvailable>
        </mods:extension>
        <mods:originInfo>
        <mods:dateIssued encoding="iso8601">2023-12-10</mods:dateIssued>
        </mods:originInfo>
        <mods:identifier type="citation">Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</mods:identifier>
        <mods:identifier type="uri">https://hdl.handle.net/20.500.13003/20140</mods:identifier>
        <mods:identifier type="doi">10.3390/biom13121769</mods:identifier>
        <mods:identifier type="essn">2218-273X</mods:identifier>
        <mods:identifier type="pmid">38136640</mods:identifier>
        <mods:identifier type="pui">L2027318853</mods:identifier>
        <mods:identifier type="scopus">2-s2.0-85180427298</mods:identifier>
        <mods:identifier type="wos">001130755700001</mods:identifier>
        <mods:abstract>Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</mods:abstract>
        <mods:language>
        <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>
        </mods:language>
        <mods:accessCondition type="useAndReproduction">Atribución 4.0 Internacional</mods:accessCondition>
        <mods:titleInfo>
        <mods:title>7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</mods:title>
        </mods:titleInfo>
        <mods:genre>research article</mods:genre>
        </mods:mods>
      </xmlData>
    </mdWrap>
  </dmdSec>
3. <amdSec ID="TMD_20.500.13003_20140">
  1. <rightsMD ID="RIG_20.500.13003_20140">
    1. <mdWrap MDTYPE="OTHER" MIMETYPE="text/plain" OTHERMDTYPE="DSpaceDepositLicense">
      1. <binData>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</binData>
      </mdWrap>
    </rightsMD>
  </amdSec>
4. <amdSec ID="FO_20.500.13003_20140_1">
  1. <techMD ID="TECH_O_20.500.13003_20140_1">
    1. <mdWrap MDTYPE="PREMIS">
      1. <xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
        <premis:premis>
        <premis:object>
        <premis:objectIdentifier>
        <premis:objectIdentifierType>URL</premis:objectIdentifierType>
        <premis:objectIdentifierValue>https://docusalut.com/bitstream/20.500.13003/20140/1/Biomolecules_2023-13-12-1769.pdf</premis:objectIdentifierValue>
        </premis:objectIdentifier>
        <premis:objectCategory>File</premis:objectCategory>
        <premis:objectCharacteristics>
        <premis:fixity>
        <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
        <premis:messageDigest>7dfe922b1883879b891207dc48aab378</premis:messageDigest>
        </premis:fixity>
        <premis:size>4072509</premis:size>
        <premis:format>
        <premis:formatDesignation>
        <premis:formatName>application/pdf</premis:formatName>
        </premis:formatDesignation>
        </premis:format>
        </premis:objectCharacteristics>
        <premis:originalName>Biomolecules_2023-13-12-1769.pdf</premis:originalName>
        </premis:object>
        </premis:premis>
        </xmlData>
      </mdWrap>
    </techMD>
  </amdSec>
5. <amdSec ID="FT_20.500.13003_20140_4">
  1. <techMD ID="TECH_T_20.500.13003_20140_4">
    1. <mdWrap MDTYPE="PREMIS">
      1. <xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">
        <premis:premis>
        <premis:object>
        <premis:objectIdentifier>
        <premis:objectIdentifierType>URL</premis:objectIdentifierType>
        <premis:objectIdentifierValue>https://docusalut.com/bitstream/20.500.13003/20140/4/Biomolecules_2023-13-12-1769.pdf.txt</premis:objectIdentifierValue>
        </premis:objectIdentifier>
        <premis:objectCategory>File</premis:objectCategory>
        <premis:objectCharacteristics>
        <premis:fixity>
        <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>
        <premis:messageDigest>32741813188e16e845ce69758fd7f7fb</premis:messageDigest>
        </premis:fixity>
        <premis:size>59543</premis:size>
        <premis:format>
        <premis:formatDesignation>
        <premis:formatName>text/plain</premis:formatName>
        </premis:formatDesignation>
        </premis:format>
        </premis:objectCharacteristics>
        <premis:originalName>Biomolecules_2023-13-12-1769.pdf.txt</premis:originalName>
        </premis:object>
        </premis:premis>
        </xmlData>
      </mdWrap>
    </techMD>
  </amdSec>
6. <fileSec>
  1. <fileGrp USE="ORIGINAL">
    1. <file ADMID="FO_20.500.13003_20140_1" CHECKSUM="7dfe922b1883879b891207dc48aab378" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_20.500.13003_20140_1" ID="BITSTREAM_ORIGINAL_20.500.13003_20140_1" MIMETYPE="application/pdf" SEQ="1" SIZE="4072509">
      1. <FLocat LOCTYPE="URL" href="https://docusalut.com/bitstream/20.500.13003/20140/1/Biomolecules_2023-13-12-1769.pdf" type="simple" />
      </file>
    </fileGrp>
  2. <fileGrp USE="TEXT">
    1. <file ADMID="FT_20.500.13003_20140_4" CHECKSUM="32741813188e16e845ce69758fd7f7fb" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_20.500.13003_20140_4" ID="BITSTREAM_TEXT_20.500.13003_20140_4" MIMETYPE="text/plain" SEQ="4" SIZE="59543">
      1. <FLocat LOCTYPE="URL" href="https://docusalut.com/bitstream/20.500.13003/20140/4/Biomolecules_2023-13-12-1769.pdf.txt" type="simple" />
      </file>
    </fileGrp>
  </fileSec>
7. <structMap LABEL="DSpace Object" TYPE="LOGICAL">
  1. <div ADMID="DMD_20.500.13003_20140" TYPE="DSpace Object Contents">
    1. <div TYPE="DSpace BITSTREAM">
      1. <fptr FILEID="BITSTREAM_ORIGINAL_20.500.13003_20140_1" />
      </div>
    </div>
  </structMap>
</mets>

mods

<?xml version="1.0" encoding="UTF-8" ?>

<mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
1. <mods:name>
  1. <mods:namePart>Costa-Bauza, Antonia</mods:namePart>
  </mods:name>
2. <mods:name>
  1. <mods:namePart>Grases, Felix</mods:namePart>
  </mods:name>
3. <mods:extension>
  1. <mods:dateAvailable encoding="iso8601">2024-01-29T12:01:01Z</mods:dateAvailable>
  </mods:extension>
4. <mods:extension>
  1. <mods:dateAccessioned encoding="iso8601">2024-01-29T12:01:01Z</mods:dateAccessioned>
  </mods:extension>
5. <mods:originInfo>
  1. <mods:dateIssued encoding="iso8601">2023-12-10</mods:dateIssued>
  </mods:originInfo>
6. <mods:identifier type="citation">Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</mods:identifier>
7. <mods:identifier type="uri">https://hdl.handle.net/20.500.13003/20140</mods:identifier>
8. <mods:identifier type="doi">10.3390/biom13121769</mods:identifier>
9. <mods:identifier type="essn">2218-273X</mods:identifier>
10. <mods:identifier type="pmid">38136640</mods:identifier>
11. <mods:identifier type="pui">L2027318853</mods:identifier>
12. <mods:identifier type="scopus">2-s2.0-85180427298</mods:identifier>
13. <mods:identifier type="wos">001130755700001</mods:identifier>
14. <mods:abstract>Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</mods:abstract>
15. <mods:language>
  1. <mods:languageTerm>eng</mods:languageTerm>
  </mods:language>
16. <mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by/4.0/</mods:accessCondition>
17. <mods:accessCondition type="useAndReproduction">open access</mods:accessCondition>
18. <mods:accessCondition type="useAndReproduction">Atribución 4.0 Internacional</mods:accessCondition>
19. <mods:titleInfo>
  1. <mods:title>7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</mods:title>
  </mods:titleInfo>
20. <mods:genre>research article</mods:genre>
</mods:mods>

ore

<?xml version="1.0" encoding="UTF-8" ?>

<atom:entry schemaLocation="http://www.w3.org/2005/Atom http://www.kbcafe.com/rss/atom.xsd.xml">
1. <atom:id>https://hdl.handle.net/20.500.13003/20140/ore.xml</atom:id>
2. <atom:link href="https://hdl.handle.net/20.500.13003/20140" rel="alternate" />
3. <atom:link href="https://hdl.handle.net/20.500.13003/20140/ore.xml" rel="http://www.openarchives.org/ore/terms/describes" />
4. <atom:link href="https://hdl.handle.net/20.500.13003/20140/ore.xml#atom" rel="self" type="application/atom+xml" />
5. <atom:published>2024-01-29T12:01:01Z</atom:published>
6. <atom:updated>2024-01-29T12:01:01Z</atom:updated>
7. <atom:source>
  1. <atom:generator>Docusalut</atom:generator>
  </atom:source>
8. <atom:title>7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</atom:title>
9. <atom:author>
  1. <atom:name>Costa-Bauza, Antonia</atom:name>
  </atom:author>
10. <atom:author>
  1. <atom:name>Grases, Felix</atom:name>
  </atom:author>
11. <atom:category label="Aggregation" scheme="http://www.openarchives.org/ore/terms/" term="http://www.openarchives.org/ore/terms/Aggregation" />
12. <atom:category scheme="http://www.openarchives.org/ore/atom/modified" term="2024-01-29T12:01:01Z" />
13. <atom:category label="DSpace Item" scheme="http://www.dspace.org/objectModel/" term="DSpaceItem" />
14. <atom:link href="https://docusalut.com/bitstream/20.500.13003/20140/1/Biomolecules_2023-13-12-1769.pdf" length="4072509" rel="http://www.openarchives.org/ore/terms/aggregates" title="Biomolecules_2023-13-12-1769.pdf" type="application/pdf" />
15. <oreatom:triples>
  1. <rdf:Description about="https://hdl.handle.net/20.500.13003/20140/ore.xml#atom">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceItem" />
    2. <dcterms:modified>2024-01-29T12:01:01Z</dcterms:modified>
    </rdf:Description>
  2. <rdf:Description about="https://docusalut.com/bitstream/20.500.13003/20140/1/Biomolecules_2023-13-12-1769.pdf">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>ORIGINAL</dcterms:description>
    </rdf:Description>
  3. <rdf:Description about="https://docusalut.com/bitstream/20.500.13003/20140/2/license_rdf">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>CC-LICENSE</dcterms:description>
    </rdf:Description>
  4. <rdf:Description about="https://docusalut.com/bitstream/20.500.13003/20140/3/license.txt">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>LICENSE</dcterms:description>
    </rdf:Description>
  5. <rdf:Description about="https://docusalut.com/bitstream/20.500.13003/20140/4/Biomolecules_2023-13-12-1769.pdf.txt">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>TEXT</dcterms:description>
    </rdf:Description>
  6. <rdf:Description about="https://docusalut.com/bitstream/20.500.13003/20140/5/Biomolecules_2023-13-12-1769.pdf.jpg">
    1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />
    2. <dcterms:description>THUMBNAIL</dcterms:description>
    </rdf:Description>
  </oreatom:triples>
</atom:entry>

qdc

<?xml version="1.0" encoding="UTF-8" ?>

<qdc:qualifieddc schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
1. <dc:title>7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</dc:title>
2. <dc:creator>Costa-Bauza, Antonia</dc:creator>
3. <dc:creator>Grases, Felix</dc:creator>
4. <dcterms:abstract>Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</dcterms:abstract>
5. <dcterms:dateAccepted>2024-01-29T12:01:01Z</dcterms:dateAccepted>
6. <dcterms:available>2024-01-29T12:01:01Z</dcterms:available>
7. <dcterms:created>2024-01-29T12:01:01Z</dcterms:created>
8. <dcterms:issued>2023-12-10</dcterms:issued>
9. <dc:type>research article</dc:type>
10. <dc:identifier>Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</dc:identifier>
11. <dc:identifier>https://hdl.handle.net/20.500.13003/20140</dc:identifier>
12. <dc:identifier>10.3390/biom13121769</dc:identifier>
13. <dc:identifier>2218-273X</dc:identifier>
14. <dc:identifier>38136640</dc:identifier>
15. <dc:identifier>L2027318853</dc:identifier>
16. <dc:identifier>2-s2.0-85180427298</dc:identifier>
17. <dc:identifier>001130755700001</dc:identifier>
18. <dc:language>eng</dc:language>
19. <dc:relation>MCIN/AEI/10.13039/501100011033</dc:relation>
20. <dc:relation>PID2019-104331RB-I00</dc:relation>
21. <dc:relation>https://doi.org/10.3390/biom13121769</dc:relation>
22. <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
23. <dc:rights>open access</dc:rights>
24. <dc:rights>Atribución 4.0 Internacional</dc:rights>
</qdc:qualifieddc>

rdf

<?xml version="1.0" encoding="UTF-8" ?>

<rdf:RDF schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
1. <ow:Publication about="oai:docusalut.com:20.500.13003/20140">
  1. <dc:title>7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</dc:title>
  2. <dc:creator>Costa-Bauza, Antonia</dc:creator>
  3. <dc:creator>Grases, Felix</dc:creator>
  4. <dc:description>Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</dc:description>
  5. <dc:date>2024-01-29T12:01:01Z</dc:date>
  6. <dc:date>2024-01-29T12:01:01Z</dc:date>
  7. <dc:date>2023-12-10</dc:date>
  8. <dc:type>research article</dc:type>
  9. <dc:identifier>Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</dc:identifier>
  10. <dc:identifier>https://hdl.handle.net/20.500.13003/20140</dc:identifier>
  11. <dc:identifier>10.3390/biom13121769</dc:identifier>
  12. <dc:identifier>2218-273X</dc:identifier>
  13. <dc:identifier>38136640</dc:identifier>
  14. <dc:identifier>L2027318853</dc:identifier>
  15. <dc:identifier>2-s2.0-85180427298</dc:identifier>
  16. <dc:identifier>001130755700001</dc:identifier>
  17. <dc:language>eng</dc:language>
  18. <dc:relation>MCIN/AEI/10.13039/501100011033</dc:relation>
  19. <dc:relation>PID2019-104331RB-I00</dc:relation>
  20. <dc:relation>https://doi.org/10.3390/biom13121769</dc:relation>
  21. <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
  22. <dc:rights>open access</dc:rights>
  23. <dc:rights>Atribución 4.0 Internacional</dc:rights>
  </ow:Publication>
</rdf:RDF>

xoai

<?xml version="1.0" encoding="UTF-8" ?>

<metadata schemaLocation="http://www.lyncode.com/xoai http://www.lyncode.com/xsd/xoai.xsd">
1. <element name="dc">
  1. <element name="contributor">
    1. <element name="author">
      1. <element name="none">
        <field name="value">Costa-Bauza, Antonia</field>
        <field name="authority">170</field>
        <field name="confidence">500</field>
        <field name="orcid_id">0000-0003-0647-4154</field>
        <field name="value">Grases, Felix</field>
        <field name="authority">340</field>
        <field name="confidence">500</field>
        <field name="orcid_id" />
        </element>
      </element>
    </element>
  2. <element name="date">
    1. <element name="accessioned">
      1. <element name="none">
        <field name="value">2024-01-29T12:01:01Z</field>
        </element>
      </element>
    2. <element name="available">
      1. <element name="none">
        <field name="value">2024-01-29T12:01:01Z</field>
        </element>
      </element>
    3. <element name="issued">
      1. <element name="none">
        <field name="value">2023-12-10</field>
        </element>
      </element>
    4. <element name="embargoEndDate">
      1. <element name="none" />
      </element>
    </element>
  3. <element name="identifier">
    1. <element name="citation">
      1. <element name="en">
        <field name="value">Costa-Bauza A, Grases F. 7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility. Biomolecules. 2023 Dec 10;13(12).</field>
        </element>
      </element>
    2. <element name="uri">
      1. <element name="none">
        <field name="value">https://hdl.handle.net/20.500.13003/20140</field>
        </element>
      </element>
    3. <element name="doi">
      1. <element name="none">
        <field name="value">10.3390/biom13121769</field>
        </element>
      </element>
    4. <element name="essn">
      1. <element name="none">
        <field name="value">2218-273X</field>
        </element>
      </element>
    5. <element name="pmid">
      1. <element name="none">
        <field name="value">38136640</field>
        </element>
      </element>
    6. <element name="pui">
      1. <element name="none">
        <field name="value">L2027318853</field>
        </element>
      </element>
    7. <element name="scopus">
      1. <element name="none">
        <field name="value">2-s2.0-85180427298</field>
        </element>
      </element>
    8. <element name="wos">
      1. <element name="none">
        <field name="value">001130755700001</field>
        </element>
      </element>
    </element>
  4. <element name="description">
    1. <element name="abstract">
      1. <element name="en">
        <field name="value">Gout is characterized by the formation of monosodium urate crystals in peripheral joints. We carried out laboratory studies to investigate the effect of adding nine different methylxanthines and two different methylated uric acid derivatives on the development of these crystals over the course of 96 h in a medium whose composition was similar to that of synovial fluid. Our results showed that 7-methylxanthine reduced or totally prevented crystal formation; 1-methylxanthine, 3-methylxanthine, 7-methyluric acid, and 1,3-dimethyluric acid had weaker effects, and the other molecules had no apparent effect. The presented results indicate that a 7-methylxanthine concentration of about 6 × 10-5 M (10 mg/L) prevented the formation of crystals for an initial urate concentration of 1.78 × 10-3 M (300 mg/L) in the presence of 0.4 M of Na+ for 96 h at 25 °C and a pH of 7.4. We attribute these results to alterations in thermodynamics, not kinetics. Our results suggest that prevention of crystallization in vivo could be achieved by direct oral administration of 7-methylxanthine or other methylxanthines that are metabolized to 7-methylxanthine. For example, the hepatic metabolism of theobromine leads to significant plasma levels of 7-methylxanthine (14% of the initial theobromine concentration) and 3-methylxanthine (6% of the initial theobromine concentration); however, 7-methyluric acid is present at very low concentrations in the plasma. It is important to consider that several of the specific molecules we examined (theobromine, caffeine, theophylline, dyphylline, etophylline, and pentoxifylline) did not directly affect crystallization.</field>
        </element>
      </element>
    2. <element name="fundingtext">
      1. <element name="en">
        <field name="value">This research was funded by the Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación, MCIN/AEI/10.13039/501100011033, with grant number PID2019-104331RB-I00.</field>
        </element>
      </element>
    </element>
  5. <element name="language">
    1. <element name="iso">
      1. <element name="en">
        <field name="value">eng</field>
        </element>
      </element>
    </element>
  6. <element name="rights">
    1. <element name="*">
      1. <field name="value">Atribución 4.0 Internacional</field>
      </element>
    2. <element name="uri">
      1. <element name="*">
        <field name="value">http://creativecommons.org/licenses/by/4.0/</field>
        </element>
      </element>
    3. <element name="accessRights">
      1. <element name="en">
        <field name="value">open access</field>
        </element>
      </element>
    </element>
  7. <element name="subject">
    1. <element name="mesh">
      1. <element name="*">
        <field name="value">Uric Acid</field>
        <field name="authority">D014527</field>
        <field name="confidence">500</field>
        <field name="value">Solubility</field>
        <field name="authority">D012995</field>
        <field name="confidence">500</field>
        <field name="value">Theobromine</field>
        <field name="authority">D013805</field>
        <field name="confidence">500</field>
        <field name="value">Caffeine</field>
        <field name="authority">D002110</field>
        <field name="confidence">500</field>
        </element>
      </element>
    2. <element name="decs">
      1. <element name="*">
        <field name="value">Cafeína</field>
        <field name="authority">DECSD002110</field>
        <field name="confidence">500</field>
        <field name="value">Solubilidad</field>
        <field name="authority">DECSD012995</field>
        <field name="confidence">500</field>
        <field name="value">Ácido Úrico</field>
        <field name="authority">DECSD014527</field>
        <field name="confidence">500</field>
        <field name="value">Teobromina</field>
        <field name="authority">DECSD013805</field>
        <field name="confidence">500</field>
        </element>
      </element>
    </element>
  8. <element name="title">
    1. <element name="en">
      1. <field name="value">7-Methylxanthine Inhibits the Formation of Monosodium Urate Crystals by Increasing Its Solubility</field>
      </element>
    </element>
  9. <element name="type">
    1. <element name="en">
      1. <field name="value">research article</field>
      </element>
    </element>
  10. <element name="issue">
    1. <element name="number">
      1. <element name="en">
        <field name="value">12</field>
        </element>
      </element>
    </element>
  11. <element name="journal">
    1. <element name="title">
      1. <element name="en">
        <field name="value">Biomolecules</field>
        </element>
      </element>
    </element>
  12. <element name="relation">
    1. <element name="projectID">
      1. <element name="en">
        <field name="value">MCIN/AEI/10.13039/501100011033</field>
        <field name="value">PID2019-104331RB-I00</field>
        </element>
      </element>
    2. <element name="publisherversion">
      1. <element name="en">
        <field name="value">https://doi.org/10.3390/biom13121769</field>
        </element>
      </element>
    </element>
  13. <element name="volume">
    1. <element name="number">
      1. <element name="en">
        <field name="value">13</field>
        </element>
      </element>
    </element>
  </element>
2. <element name="bundles">
  1. <element name="bundle">
    1. <field name="name">ORIGINAL</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">Biomolecules_2023-13-12-1769.pdf</field>
        <field name="originalName">Biomolecules_2023-13-12-1769.pdf</field>
        <field name="description" />
        <field name="format">application/pdf</field>
        <field name="size">4072509</field>
        <field name="url">https://docusalut.com/bitstream/20.500.13003/20140/1/Biomolecules_2023-13-12-1769.pdf</field>
        <field name="checksum">7dfe922b1883879b891207dc48aab378</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">1</field>
        <field name="drm">open access</field>
        </element>
      </element>
    </element>
  2. <element name="bundle">
    1. <field name="name">CC-LICENSE</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">license_rdf</field>
        <field name="originalName">license_rdf</field>
        <field name="format">application/rdf+xml; charset=utf-8</field>
        <field name="size">908</field>
        <field name="url">https://docusalut.com/bitstream/20.500.13003/20140/2/license_rdf</field>
        <field name="checksum">0175ea4a2d4caec4bbcc37e300941108</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">2</field>
        <field name="drm">open access</field>
        </element>
      </element>
    </element>
  3. <element name="bundle">
    1. <field name="name">LICENSE</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">license.txt</field>
        <field name="originalName">license.txt</field>
        <field name="format">text/plain; charset=utf-8</field>
        <field name="size">2656</field>
        <field name="url">https://docusalut.com/bitstream/20.500.13003/20140/3/license.txt</field>
        <field name="checksum">2950fb5652400e2aa8d1e74e7b3e66ca</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">3</field>
        <field name="drm">open access</field>
        </element>
      </element>
    </element>
  4. <element name="bundle">
    1. <field name="name">TEXT</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">Biomolecules_2023-13-12-1769.pdf.txt</field>
        <field name="originalName">Biomolecules_2023-13-12-1769.pdf.txt</field>
        <field name="description">Extracted text</field>
        <field name="format">text/plain</field>
        <field name="size">59543</field>
        <field name="url">https://docusalut.com/bitstream/20.500.13003/20140/4/Biomolecules_2023-13-12-1769.pdf.txt</field>
        <field name="checksum">32741813188e16e845ce69758fd7f7fb</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">4</field>
        <field name="drm">open access</field>
        </element>
      </element>
    </element>
  5. <element name="bundle">
    1. <field name="name">THUMBNAIL</field>
    2. <element name="bitstreams">
      1. <element name="bitstream">
        <field name="name">Biomolecules_2023-13-12-1769.pdf.jpg</field>
        <field name="originalName">Biomolecules_2023-13-12-1769.pdf.jpg</field>
        <field name="description">IM Thumbnail</field>
        <field name="format">image/jpeg</field>
        <field name="size">20732</field>
        <field name="url">https://docusalut.com/bitstream/20.500.13003/20140/5/Biomolecules_2023-13-12-1769.pdf.jpg</field>
        <field name="checksum">dd52f8b4d5fe874f00e5b451716e3877</field>
        <field name="checksumAlgorithm">MD5</field>
        <field name="sid">5</field>
        <field name="drm">open access</field>
        </element>
      </element>
    </element>
  </element>
3. <element name="others">
  1. <field name="handle">20.500.13003/20140</field>
  2. <field name="identifier">oai:docusalut.com:20.500.13003/20140</field>
  3. <field name="lastModifyDate">2024-01-30 01:36:13.058</field>
  4. <field name="drm">open access</field>
  </element>
4. <element name="repository">
  1. <field name="name">Docusalut</field>
  2. <field name="mail">docusalut@bibliosalut.com</field>
  </element>
5. <element name="license">
  1. <field name="bin">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</field>
  </element>
</metadata>